Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment.
Wanchaijiraboon P, Teeyapun N, Pakvisal N, Sainamthip P, Susiriwatananont T, Zungsontiporn N, Suntronwong N, Vichaiwattana P, Klinsawat W, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Poovorawan Y, Luangdilok S. Wanchaijiraboon P, et al. Among authors: pakvisal n. Vaccines (Basel). 2022 Oct 5;10(10):1662. doi: 10.3390/vaccines10101662. Vaccines (Basel). 2022. PMID: 36298528 Free PMC article.
Safety and Immunogenicity of Homologous and Heterologous Adenoviral-Vectored and mRNA COVID-19 Vaccine Regimens in Radiotherapy Patients.
Prayongrat A, Noppaving P, Chobarporn T, Sudhinaraset N, Teeyapun N, Pakvisal N, Jantarabenjakul W, Sophonphan J, Lertbutsayanukul C, Poovorawan Y. Prayongrat A, et al. Among authors: pakvisal n. Vaccines (Basel). 2023 Jun 23;11(7):1135. doi: 10.3390/vaccines11071135. Vaccines (Basel). 2023. PMID: 37514951 Free PMC article.
Efficacy, Safety, and Patient-Reported Outcomes of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Thailand: A Multicenter Prospective Study.
Charonpongsuntorn C, Tanasanvimon S, Korphaisarn K, Payapwattanawong S, Siripoon T, Pakvisal N, Juengsamarn J, Phaibulvatanapong E, Chindaprasirt J, Prasongsook N, Udomdamrongkul K, Ngamphaiboon N, Sirachainan E. Charonpongsuntorn C, et al. Among authors: pakvisal n. JCO Glob Oncol. 2022 Nov;8:e2200205. doi: 10.1200/GO.22.00205. JCO Glob Oncol. 2022. PMID: 36455172 Free PMC article.
Differential expression of immune-regulatory proteins C5AR1, CLEC4A and NLRP3 on peripheral blood mononuclear cells in early-stage non-small cell lung cancer patients.
Pakvisal N, Kongkavitoon P, Sathitruangsak C, Pornpattanarak N, Boonsirikamchai P, Ouwongprayoon P, Aporntewan C, Chantranuwatana P, Mutirangura A, Vinayanuwattikun C. Pakvisal N, et al. Sci Rep. 2022 Nov 2;12(1):18439. doi: 10.1038/s41598-022-21891-0. Sci Rep. 2022. PMID: 36323738 Free PMC article.
Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.
Luangdilok S, Wanchaijiraboon P, Pakvisal N, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Sainamthip P, Suntronwong N, Vichaiwattana P, Wanlapakorn N, Poovorawan Y, Teeyapun N, Tanasanvimon S. Luangdilok S, et al. Among authors: pakvisal n. Vaccines (Basel). 2022 Sep 26;10(10):1613. doi: 10.3390/vaccines10101613. Vaccines (Basel). 2022. PMID: 36298478 Free PMC article.
Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study.
Teeyapun N, Luangdilok S, Pakvisal N, Sainamthip P, Mingmalairak S, Poovorawan N, Sitthideatphaiboon P, Parinyanitikul N, Sriuranpong V, Namkanisorn T, Inthasuwan P, Angspatt P, Wongchanapat P, Bamrungnam A, Leeleakpai N, Uttha S, Jaichum S, Kongkaew P, Suksanong C, Veranitinun R, Prasomphol A, Sartsuk C, Patcharajutanon C, Preaprang S, Choengsamor H, Phongwan R, Preeyasaksa C, Phaibulvatanapong E, Suntronwong N, Yorsaeng R, Vichaiwattana P, Wanlapakorn N, Kerr SJ, Poovorawan Y, Wanchaijiraboon P, Tanasanvimon S. Teeyapun N, et al. Among authors: pakvisal n. EClinicalMedicine. 2022 Oct;52:101608. doi: 10.1016/j.eclinm.2022.101608. Epub 2022 Aug 11. EClinicalMedicine. 2022. PMID: 35971500 Free PMC article.
Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.
Pakvisal N, Sainamthip P, Teeyapun N, Luangdilok S, Wanlapakorn N, Yorsaeng R, Poovorawan Y, Pakvisal P, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Tanasanvimon S, Wanchaijiraboon P. Pakvisal N, et al. Hum Vaccin Immunother. 2022 Nov 30;18(6):2094149. doi: 10.1080/21645515.2022.2094149. Epub 2022 Jul 1. Hum Vaccin Immunother. 2022. PMID: 35776836 Free PMC article.
A prospective randomized study comparing the efficacy between povidone-iodine gargling and benzydamine hydrochloride for mucositis prevention in head and neck cancer patients receiving concurrent chemoradiotherapy.
Kannarunimit D, Chotirut A, Prayongrat A, Pakvisal N, Sitthideatphaiboon P, Lertbutsayanukul C, Kitpanit S, Chakkabat C, Vinayanuwattikun C. Kannarunimit D, et al. Among authors: pakvisal n. Heliyon. 2023 Apr 11;9(4):e15437. doi: 10.1016/j.heliyon.2023.e15437. eCollection 2023 Apr. Heliyon. 2023. PMID: 37151677 Free PMC article.
Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.
Wanchaijiraboon P, Sainamthip P, Teeyapun N, Luangdilok S, Poovorawan Y, Wanlapakorn N, Tanasanvimon S, Sriuranpong V, Susiriwatananont T, Zungsontiporn N, Pakvisal N. Wanchaijiraboon P, et al. Among authors: pakvisal n. Vaccines (Basel). 2023 Feb 3;11(2):356. doi: 10.3390/vaccines11020356. Vaccines (Basel). 2023. PMID: 36851234 Free PMC article.